Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Michael L. Salgaller"'
Autor:
Michael L Salgaller, Linda M. Liau
Publikováno v:
Reviews on Recent Clinical Trials. 1:265-281
Glioblastoma, the most highly aggressive and lethal form of brain cancer, has been a particular challenge to treat in terms of improving a patient's quality of life and outcome. Each of the current treatment options is limited due to factors intrinsi
Autor:
Gary Pestano, Marnix L. Bosch, Michael L Salgaller, Edward Howard, Julie Anna Mcearchern, Yaling Zhou
Publikováno v:
Cancer Immunology, Immunotherapy. 52:413-422
Active immunotherapy of cancer requires the availability of a source of tumor antigens. To date, no such antigen associated with lung cancer has been identified. We have therefore investigated the ability of dendritic cells (DC) to capture whole irra
Publikováno v:
Journal of Immunotherapy. 25:289-303
The immunotherapy of cancer is predicated on the belief that it is possible to generate a clinically meaningful antitumor response that provides patient benefit, such as improvement in the time to progression or survival. Indeed, immunotherapeutics w
Autor:
Michael L Salgaller
Publikováno v:
Expert Opinion on Biological Therapy. 2:265-278
Standard of care for non-small cell lung cancer (NSCLC) (surgery, chemotherapy and radiation) may enhance patient survival but the enhancement is typically transient and quite uncommon with advanced disease. Researchers and medical professionals are
Autor:
Michael L Salgaller
Publikováno v:
Expert Opinion on Investigational Drugs. 9:1217-1229
Standard treatments for adenocarcinoma of the prostate, such as surgery, hormones, radiation and chemotherapy, often achieve a clinical response, but this is usually short-lived. Prostate cancer frequently recurs and second-line therapies have a poor
Autor:
Michael L Salgaller
Publikováno v:
Expert Opinion on Investigational Drugs. 9:1413-1417
A major session at this annual gathering of the cancer researchers from around the globe dealt with the current state of immunotherapy for cancer. Immunotherapy is a form of cancer treatment that enhances its scientific promise and legitimacy with ea
Publikováno v:
Cancer. 86:2674-2683
Autor:
Lori A. Jones, Michael L Salgaller
Publikováno v:
Expert Opinion on Investigational Drugs. 8:1007-1016
Involving a delicate balance of cell types, the interaction between the immune system and disease or abnormality in the human body is complex. Moreover, the mere presence of antigen and immune cells is necessary, yet insufficient to elicit immune rea
Autor:
Steven J. Monahan, Michael L. Salgaller, Ronnie A. Childs, Patricia A. Lodge, Alton L. Boynton, Gerald P. Murphy, Anil Sehgal, Joanne G. McLean
Publikováno v:
Journal of Immunotherapy. 22:346-355
Antigen-specific immunotherapy of cancer depends on a consistent source of well-defined protein antigen. Production of recombinant protein offers the obvious solution to this problem but few comparisons of recombinant and native proteins in cellular
Autor:
S.J. Simmons, Alton L. Boynton, Michael L Salgaller, M. Rogers, Gerald P. Murphy, Haakon Ragde, M.J. Troychak, G.M. Kenny, Benjamin A. Tjoa, Abdel-Aziz A. Elgamal
Publikováno v:
The Prostate. 39:54-59
BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects adm